Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This is a multicenter, randomized, double‐blind, placebo‐controlled, Phase 3 study designed to compare the efficacy and safety of tislelizumab + either cisplatin or carboplatin + gemcitabine versus placebo+ either cisplatin or carboplatin + gemcitabine in approximately 420 participants with locally advanced or metastatic urothelial carcinoma who have not received prior systemic therapy.
Epistemonikos ID: 6c4358247c40e3ebbc6f17be48b3a4fbb44514b5
First added on: May 22, 2024